Changes in Patient Functioning and Disability: Results from Two Phase 3 Double-Blind Placebo-Controlled Clinical Trials Evaluating Galcanezumab for Episodic Migraine Prevention (EVOLVE-1 and EVOLVE-2)

被引：0
|
作者：
Ford, J. [1 ]
Ayer, D. [1 ]
Zhang, Q. [2 ]
Carter, J. [2 ]
Skljarevski, V [2 ]
Aurora, S. [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
HEADACHE | 2018年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PS37
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [21] Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
    Janet Ford
    Cristina Tassorelli
    Elizabeth Leroux
    Shufang Wang
    David Ayer
    Russell Nichols
    Holland Detke
    Quality of Life Research, 2021, 30 : 105 - 115
  • [22] Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
    Ford, Janet
    Tassorelli, Cristina
    Leroux, Elizabeth
    Wang, Shufang
    Ayer, David
    Nichols, Russell
    Detke, Holland
    QUALITY OF LIFE RESEARCH, 2021, 30 (01) : 105 - 115
  • [23] Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
    Skljarevski, Vladimir
    Matharu, Manjit
    Millen, Brian A.
    Ossipov, Michael H.
    Kim, Byung-Kun
    Yang, Jyun Yan
    CEPHALALGIA, 2018, 38 (08) : 1442 - 1454
  • [24] CHANGES IN PATIENT FUNCTIONING AND DISABILITY FROM TWO PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL STUDIES OF GALCANEZUMAB
    Ford, J. H.
    Ayer, D. W.
    Zhang, Q.
    Carter, J. N.
    Skljarevski, V.
    Aurora, S. K.
    CEPHALALGIA, 2018, 38 : 82 - 82
  • [25] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (1):
  • [26] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Stephen D. Silberstein
    Virginia L. Stauffer
    Katie A. Day
    Sarah Lipsius
    Maria-Carmen Wilson
    The Journal of Headache and Pain, 2019, 20
  • [27] Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
    Stephen D. Silberstein
    Virginia L. Stauffer
    Katie A. Day
    Sarah Lipsius
    Maria-Carmen Wilson
    The Journal of Headache and Pain, 2019, 20
  • [28] Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies (vol 60, pg 2202, 2020)
    Smitherman, T. A.
    HEADACHE, 2022, 62 (01): : 114 - 116
  • [29] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Subgroup Analyses of Efficacy by Low-Versus High-Frequency of Migraine Headaches
    Silberstein, Stephen
    Stauffer, Virginia L.
    Day, Kathleen A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    NEUROLOGY, 2019, 92 (15)
  • [30] Phase 3 studies (EVOLVE-1 & EVOLVE-2) of galcanezumab in episodic migraine: subgroup analyses of efficacy by low-versus high-frequency of migraine headaches
    Silberstein, Stephen
    Stauffer, Virginia L.
    Day, Katie
    Zhang, Qi
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
12345